Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-07-29 |
Location
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
Tags
MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | Phase
Phase 3
|
Date Added 2022-08-01 |
Location
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-08-08 |
Location
Singapore
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2022-12-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
HX008, Investigator's Choice Chemotherapy |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | Phase
Phase 1, Phase 2
|
Date Added 2023-01-05 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, Regorafenib |
Tags
MSS/ MMRp
|
| NCT ID NCT05677113 |
TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver | Phase
Phase 2
|
Date Added 2023-01-10 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Placebo, QBECO |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05676190 |
TitleClinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer | Phase
Not Applicable
|
Date Added 2023-01-09 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-04-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Disitamab vedotin, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT06300463 |
TitlePlatform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Phase
Phase 2
|
Date Added 2024-03-08 |
Location
New York, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AGEN1423, Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2024-03-29 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
